Introduction
The central nervous system (CNS) is the organ second most frequently involved in mitochondrial disorders. 1 Among the various clinical CNS manifestations, such as stroke-like episodes, movement disorders, hypopituitarism, cognitive dysfunction, dementia, psychosis, transverse syndrome, or motor neuron disease, epilepsy is one of the most frequent. 2 This mini-review focuses on the description of syndromic and non-syndromic mitochondrial disorders in which epilepsy is a dominant (frequent seizures) or collateral (rare seizures) feature of the phenotype.
Epilepsy in mitochondrial disorders
Epilepsy may be a phenotypic feature of syndromic as well as non-syndromic mitochondrial disorders. Syndromic mitochondrial disorders with frequent seizures include Alpers-Huttenlochersyndrome (AHS), 3, 4 ataxia-neuropathy spectrum (ANS) including mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia with neuropathy, dysarthria and ophthalmoparesis (SANDO)-syndrome, 3 Leigh-syndrome, [5] [6] [7] mitochondrial enceph-or liver failure following medication with antiepileptic drugs (AEDs). 3, 21 AHS is due to POLG1 mutations causing mtDNA depletion. Two children, who had developed refractory seizures and myoclonic fits since age 20 and 60 days respectively, were lastly diagnosed as AHS upon additional clinical features and biochemical investigations revealing complex-IV (COX)-deficiency. 14 In the first case EEG showed low-amplitude, polyspikes, polyspike-waves, and very slow waves of high amplitude alternating with a trace of burst-suppression activity. 14 In the second case low-amplitude polyspikes, polyspike-waves, and occasionally desynchronization of basal trace were recorded. In the first case cortical blindness and severe hepatic failure developed while receiving valproate. 14 In a recent report about a single patient drug-refractory status epilepticus could be terminated only after functional hemispherectomy. 22 
ANS (ataxia neuropathy spectrum)
The ataxia neuropathy spectrum includes the mitochondrial recessive ataxia-syndrome (MIRAS) and sensory ataxia, neuropathy, dysarthria and ophthalmoplegia (SANDO)-syndrome. 3 MIRAS may manifest as childhood-onset encephalopathy with hepatopathy, juvenile-onset refractory epilepsy and migraine-like headache, or as adult-onset ataxia and neuropathy. 23 It is clinically characterized by recessive ataxia, coordination deficits, dysarthria, choreoathetosis, personality change, cognitive impairment, hemianopsia, neuropathy, or epilepsy. 24 MIRAS is most frequently due to POLG1 mutations, such as the mutations p.748W>S in cis or p.1143E>G. 24 
Leigh-syndrome
Leigh-syndrome is either due to mtDNA or nDNA mutations. Leigh syndrome due to nDNA mutations is much more frequent than due to mtDNA mutations. Leigh-syndrome due to mtDNA mutations follows a maternal trait of inheritance. Maternallyinherited Leigh syndrome is most frequently due to the mutation m.8993T>G in the ATP6 gene. 2, 25 Leigh syndrome due to nDNA mutations is phenotypically not at variance from Leigh-syndrome due to mtDNA mutations. 25 Also the typical, symmetric MRI abnormalities are similar in both groups. Epilepsy is, among other CNS abnormalities, a typical phenotypic feature of Leigh-syndrome. 25 Most frequently these patients develop generalized tonic-clonic seizures. 26 Only rarely epilepsia partialis continua 27 or West-syndrome (infantile spasms) 28 have been reported.
Epilepsy was one of the main clinical manifestations in addition to psychomotor retardation and quadruspasticity in a 5 monthsold child with Leigh-syndrome due to a missense mutation in the SDHA gene. 29 When comparing 5 patients with Leigh-syndrome and West-syndrome with 7 patients with Leigh-syndrome but without West-syndrome, it turned out that onset of Leighsyndrome was <10 months in all 5 patients with Leigh-and West-syndrome and that infantile spasms developed in all five patients after detection of Leigh-syndrome. 7 There were indications that the development of West-syndrome was associated with early-onset Leigh-syndrome, spasticity, nystagmus, apnea, poor feeding, or cardiac involvement. 7 West-syndrome did not influence the prognosis of Leigh-syndrome or vice versa. 7 In a study on 5 patients with Leigh-syndrome and complex-I, complex-IV, complex-V, pyruvate carboxylase, or pyruvate-dihydrogenasedeficiency respectively, epilepsy was the initial manifestation in two. 9 Three patients had partial seizures, one patient generalized tonic seizures, and one patient myoclonic seizures. Focal or multifocal sharp waves in the occipital projection were recorded in three patients. Only in one of these patients the EEG was indicative of generalized epilepsy. 9 A status epilepticus was reported in a seven months-old girl with Leigh-syndrome, diagnosed upon additional clinical features, such as developmental delay and regression of achieved milestones, and typical features on MRI. 30 In a single patient with juvenile-onset Leigh-syndrome due to the mutation m.14487T>C epilepsy was one of the cardinal phenotypic features in addition to optic atrophy, ataxia, and dystonia. 31 Epilepsy was also reported in a 17 months-old infant with lethargy, anorexia, respiratory insufficiency, motor delay, inappropriate secretion of antidiuretic hormone, and symmetrical lesions in the cervical cord and lower brain stem. 32 Leighsyndrome in this patient was due to the m.8344A>G mutation. Generalized epilepsy was the initial clinical manifestation in a 12yo previously healthy Chinese boy carrying the transition m.13513G>A who later developed loss of vision and quadruspasticity. 33 Epilepsy was also part of the phenotype in another patient with maternally inherited Leigh-syndrome. 6 Only few patients with maternally inherited Leigh-syndrome predominantly present with epilepsy but lack other typical phenotypic features of the syndrome. 
MELAS (mitochondrial encephalopathy, lactacidosis and strokelike episodes)
MELAS is clinically characterized by stroke-like episodes, encephalopathy, epilepsy, and lactacidosis. 8 In 80% of the cases MELAS is due to the transition m.3243A>G in the tRNA(Leu) gene. MELAS may be associated with partial seizures or generalized seizures, including status epilepticus. 34 In a study on 31 patients with a mitochondrial disorder and epilepsy, 5 were classified as MELAS-syndrome. 9 Seizure onset was between 14 and 39y of age in these patients. Prior to onset of seizures, these patients had developed stroke-like episodes (n = 3), migraine (n = 2), diabetes (n = 2), or psychomotor delay (n = 2). Four patients had developed partial seizures and one tonic-clonic seizures. EEG-recordings in these patients showed diffuse slowing (n = 4), unilateral slowing (n = 1), focal posterior sharp waves (n = 4), symmetrical sharp waves (n = 2), or photosensitivity (n = 2). 9 In other patients with MELAS-syndrome recurrent complex partial seizures and nonconvulsive status epilepticus were reported. 35 In patients who carry the m.3243A>G mutation and predominantly manifest with diabetes and deafness but variably develop additional phenotypic features, epilepsy has been only rarely reported. 36 In two German families with maternally-inherited diabetes and deafness due to the m.3243A>G mutation, some of the family members presented with seizures, Parkinson's disease, and endocrinopathies. 36 In a three-generation family carrying the m.3243A>G mutation, generalized epilepsy with tonic-clonic seizures was a dominant feature of the phenotype. Myoclonic epilepsy, myopathy and sensory ataxia (MEMSA) represents a disorder previously referred as spinocerebellar ataxia with epilepsy (SCAE). 3 MEMSA is most frequently due to POLG1 mutations. 38 MEMSA is clinically characterized by ataxia, myoclonic epilepsy, and myopathy. Cerebellar ataxia is generally the first sign beginning in early adulthood. 3 Myopathy is the next manifestation and may be distal or proximal, or may manifest exclusively as exercise intolerance. Though the prevalence of MEMSA is low, myoclonic epilepsy is an invariable feature of these patients. Epilepsy develops in later years and begins often focally in the upper limbs with secondary generalization. 3 Seizures may be refractory to conventional AED treatment, and even to anaesthesia. Recurrent seizure activity is usually accompanied by progression of the encephalopathy. 
MERRF (myoclonic epilepsy with ragged-red fibers)
The main clinical manifestations of MERRF-syndrome include ataxia, myopathy and myoclonic epilepsy. 10, 11 The mutation most frequently causing MERRF-syndrome is the transition m.8344A>G. Myoclonic epilepsy was also reported in a female carrying the m.8363G>A mutation. 12 Her daughter and half-sister were affected by Leigh-syndrome and died both in early infancy. 12 In a study on 5 patients with MERRF-syndrome onset of epilepsy ranged between 7 and 50y of age. 9 Seizures were classified as myoclonic (n = 5) or as tonic-clonic (n = 1). EEG showed diffuse slowing (n = 2), focal posterior sharp waves (n = 1), polyspikewaves (n = 3), or symmetric sharp waves with photosensitivity (n = 1). Infantile onset spinocerebellar ataxia is clinically characterized by infantile-onset spino-cerebellar ataxia due to mutations in the POLG1 gene. 39 Infantile onset spinocerebellar ataxia is occasionally associated with epilepsy. Particularly in the late stages of the disease, myoclonic jerks and focal seizures have been reported.
14 Among 19 Finnish patients with infantile-onset spinocerebellar ataxia epilepsy was a late clinical manifestation of the disease. 40 Epilepsy with tonic-clonic seizures was also a phenotypic feature in other patients with infantile-onset spinocerebellar ataxia.
13,40
KSS (Kearns-Sayre-syndrome)
KSS is clinically characterized by CPEO, pigmentary retinopathy, cardiac conduction defects and variable additional phenotypic manifestations. KSS is due to single large-scale mtDNA deletions. Epilepsy is not a classical phenotypic manifestation of KSS but has been observed in single patients. Long-term follow-up EEGrecordings in KSS patients usually show only generalized slowing of background activity. 41 Generalized epilepsy since childhood was reported in a 33yo patient with KSS. 16 Partial and generalized seizures were reported in a patient with incomplete KSS. Leucencephalopathy with brain stem and spinal cord involvement and lactacidosis (LBSL) is clinically characterized by slowly progressive pyramidal, cerebellar, and dorsal column dysfunction, and decreased vibration and position sense. 42 Additional manifestations include mild mental impairment, slowly progressive ataxia, spasticity, or neuropathy. 18 LBSL is due to mutations in the DARS2 gene encoding the mitochondrial aspartyl-tRNA syntethase. 18 LBSL has an infantile or juvenile onset and patients become wheel-chair bound by their teens or twenties. 19 Only single patients develop epilepsy. 
LHON (Leber's hereditary optic neuropathy)
Leber's hereditary optic neuropathy (LHON) is clinically characterized by severe central loss of vision and optic atrophy most frequently affecting young men. 17 Leber's hereditary optic neuropathy is most frequently due to one of the three primary homoplasmic LHON mutations m.3460G>A, m.11778G>A, or m.14484T>C in the ND1, ND4, or ND6 gene respectively. 6 Occasionally, patients may develop extra-ocular manifestations such as migraine, mental retardation, or epilepsy (LHON plus). 17 In some of these patients epilepsy may even precede the onset of ocular manifestations. 43 Occasionally, epilepsy may be the dominant manifestation of the disease and may be refractory to AED treatment. 44 
NARP (neuropathy, ataxia and retinitis pigmentosa)
NARP syndrome is clinically characterized by neuropathy, ataxia and retinitis pigmentosa. The mutation most frequently responsible for the phenotype is the transition m.8993T>G in the ATP6 gene. 45 Epilepsy with severe seizures is particularly reported in early-onset forms of the disease but is rare in cases with adolescent or adult onset. 20 Single patients may present without seizures but may show epileptic discharges on EEG. 20 Such patients may develop epilepsy with progression of the mitochondrial disorder. 20 Seizures were also reported in a study on an eightmember family carrying the m.8993T>G mutation with atypical phenotype. 5 In a single patient with NARP-syndrome progressive myoclonic epilepsy was reported. 46 
Non-syndromic mitochondrial disorders
Several non-syndromic mitochondrial disorders have been reported in which epilepsy was one of the phenotypic features. 47 In dizygotic twins the m.8363G>A mutation manifested phenotypically with mental retardation, ataxia, deafness, myopathy, and myoclonic epilepsy. 48 No detailed information about the AED treatment and the course of epilepsy were provided. Among 4 adult patients with non-syndromic mitochondrial disorder, seizures were tonic-clonic (n = 1), myoclonic (n = 1), motor (n = 1), and somatosensory (n = 1). 9 EEG showed diffuse slowing (n = 2), focal anterior sharp waves (n = 1), symmetrical polyspikewaves (n = 1), and photosensitivity (n = 1). Among the two patients with partial seizures, one experienced episodes of epilepsia partialis continua. Among the two patients with generalized seizures one had rare tonic-clonic seizures associated with progressive mental impairment and cerebral atrophy. The first patient had sharp-waves over the parieto-occipital projection and the other symmetric polyspike-wave complexes on photostimulation. 9 In a study on 12 patients with non-syndromic mitochondrial disorder, epilepsy was the initial manifestation in seven of them. Eight of these patients had partial seizures and four generalized seizures. The mitochondrial disorder was due to PDH-deficiency in 6, complex-IV deficiency in 3, and due to multiple respiratory chain complex deficiencies in 3 patients. In a Japanese family carrying the m.3291T>C mutation (tRNA gene), the phenotypic presentation included cerebellar ataxia, myopathy, headache, and myoclonic epilepsy with considerable intra-familial heterogeneity, observed with many pathogenic tRNA point mutations. 49 Among seven families with mutations in the tRNASer(UCN) gene, those carrying the m.7472insC or the m.7512T>C mutation presented with myoclonic epilepsy, deafness, ataxia, and cognitive impairment. 50 Epilepsy was also a feature of the phenotypic spectrum in a number of other non-syndromic mitochondrial disorders. 51 
Frequency of epilepsy in mitochondrial disorders
There are no systematic studies available in how many of the patients with syndromic or non-syndromic mitochondrial disorders epilepsy occurs, but epilepsy is definitively more frequent in some mitochondrial disorders than in others. In some of the mitochondrial disorders epilepsy even dominates the phenotype, such as in AlpersHuttenlocher-syndrome, ataxia-neuropathy spectrum, Leigh-syndrome, MELAS-syndrome, MEMSA, or MERRF-syndrome (Table 1 ). In the other syndromic mitochondrial disorders epilepsy occurs in only some of the patients. Disregarding the frequency of epilepsy within a MID, the intra-and inter-familial phenotypic variability of seizures is high. Among pediatric patients with epilepsy due to a mitochondrial disorder, half of the patients present with a nonsyndromic phenotypes. 52 
Characterization of epilepsy in mitochondrial disorders
Only few studies are available, which describe the clinical and EEG characteristics of epilepsy in mitochondrial disorders. In a study on 31 patients with a mitochondrial disorder and epilepsy, epilepsy was found as the initial manifestation in 53% of them. 9 Mitochondrial disorders were classified as non-syndromic in 43% of the adult-onset cases and in 70% of the infantile-onset cases. 9 In 71% of the patients partial seizures with predominantly motor symptoms and focal or multifocal EEG epileptiform activity characterized the epileptic presentation. 3 Myoclonic seizures were found in only 16% of the patients. They all presented with MERRFsyndrome due to the classical m.8344A>G mutation. 9 Photoparoxysmal EEG responses were recorded in patients with MERRFsyndrome, patients with MELAS-syndrome, in patients with Leighsyndrome, and in patients with non-syndromic mitochondrial disorders. 9 In patients with MERRF-syndrome generalized epileptiform discharges or generalized photoparoxysmal responses during intermittent photic stimulation may be recorded. 53 
Treatment of epilepsy in mitochondrial disorders
Treatment of epilepsy in mitochondrial disorders is generally not at variance from treatment of epilepsy due to other causes. Some peculiarities of epilepsy treatment in mitochondrial disorders, however, should be kept in mind. Concerning the use of AEDs in patients with mitochondrial disorders it is important to avoid AEDs with mitochondrion-toxic side-effects, since they may cause severe, fulminant, sometimes fatal side-effects, may trigger or worsen epilepsy, or may make epilepsy intractable. The AED with the most well-known mitochondrial toxicity is valproic-acid (VPA). Particularly, in patients carrying POLG1 mutations (e.g. Alpers-Huttenlocher syndrome) or in patients with MERRFsyndrome VPA may exhibit a deleterious effect why VPA but also other mitochondrion-toxic MIDs should be avoided in these conditions. In two patients with Alpers-Huttenlocher syndrome and drug-resistant epilepsy, administration of VPA caused irreversible liver failure. 54 Because VPA causes liver failure also in other patients with POLG1 mutations, it is absolutely contraindicated in these patients. Some authors even claim to test children with epilepsy for POLG1-mutations before starting VPA. 55 Only in patients with mitochondrial disorders due to mutations other than POLG1, VPA may be tried in case of drug-resistant status epilepticus. 56 Replacement of VPA by other AEDs can markedly improve the outcome of these patients. 57 Alternatives to classic AED treatment of epilepsy in patients with mitochondrial disorders include ketogenic diet (ratio of fat to carbohydrates and protein is 3:1), L-arginine, 58 pyruvate, 59 or ketamine. 60 In a patient with Leigh-syndrome due to a mutation in the PDH E1a-gene, generalized tonic-clonic seizures improved upon administration of sodium-pyruvate in a dosage of 0.5 g/kg/d orally. 59 Ketogenic diet results in the production of ketone bodies, which consecutively reduce oxidative stress, reduce excitability of central neurons, inhibit glycolysis, and retard epileptogenesis. 61 Ketogenic diet has been shown beneficial in various patients with epilepsy from a mitochondrial disorder. [62] [63] [64] [65] Vagal nerve stimulation has been tried in single patients with mitochondrial disorders and myoclonic seizures or focal seizures with secondary generalization, but did not show a beneficial effect. 66 
Death from epilepsy in mitochondrial disorders
Death from epilepsy in mitochondrial disorders has been only rarely reported and may occur in form of sudden unexplained death in epilepsy (SUDEP), intractable epileptic state, or secondary complications of seizures, such as intracerebral bleeding or head trauma. In a family with maternally inherited Leigh-syndrome and myoclonic epilepsy due to the m.8344A>G mutation several family members had died suddenly during infancy. 67 In a study on 6 adults with non-syndromic mitochondrial disorder four of them died unexpectedly during myoclonic status epilepticus. 68 
Conclusions
Mitochondrial disorders are an important cause of epilepsy, which may be a phenotypic feature not only of syndromic forms but also of non-syndromic conditions. In some mitochondrial disorders the clinical presentation is even dominated by seizures. In the majority of the mitochondrial disorders, however, epilepsy is only a collateral feature of the phenotype but there is broad phenotypic heterogeneity such that single patients may predominantly present with epilepsy even if the mitochondrial disorder is usually not associated with epilepsy as a dominant manifestation of the disease. Though generally all types of seizures occur in mitochondrial disorders, some are more prevalent than others. Most frequently patients present with partial or generalized tonicclonic or myoclonic seizures. Treatment of epilepsy in mitochondrial disorders is not at variance from treatment of epilepsy due to other causes but care should be taken to avoid mitochondriontoxic antiepileptic drugs. Which of the antiepileptic drugs are truly mitochondrion-toxic and which is the pathogenetic background of the mitochondrion-toxic effect of an AED remains, however, elusive in most of the frequently applied AEDs. Further research is warranted to elucidate the pathogenetic background of epilepsy in mitochondrial disorders and to optimize treatment in these patients. 
